Gut & Microbiome Health: SIBO, Leaky Gut, IBS, IBD & the Gut-Brain Axis

Introduction

The gut is far more than a digestive organ. It is the seat of the immune system, a major producer of neurotransmitters, a critical regulator of hormonal balance, and — via the gut-brain axis — a direct communicator with the central nervous system. When gut health breaks down, the consequences extend far beyond digestive discomfort, rippling outward to affect immunity, mental health, metabolism, hormonal balance, and neurological function.

Gut disorders are among the most prevalent chronic conditions globally. Irritable bowel syndrome (IBS) affects 10–15% of the world population; inflammatory bowel disease (IBD) affects over 6 million people in the US alone; small intestinal bacterial overgrowth (SIBO) is estimated to underlie up to 80% of IBS cases; and intestinal hyperpermeability ("leaky gut") is increasingly recognized as a driver of systemic inflammatory and autoimmune disease.

This article provides a comprehensive deep dive into the major gut health conditions — SIBO, leaky gut, IBS, and IBD — and the gut-brain axis, with evidence-based integrative strategies for restoration. For a foundational overview of the gut microbiome, see our Gut Microbiome guide.

Part I: Small Intestinal Bacterial Overgrowth (SIBO)

What Is SIBO?

SIBO occurs when bacteria that normally reside in the large intestine colonize the small intestine in excessive numbers. The small intestine is designed to be relatively sterile — its primary role is nutrient absorption, not fermentation. When bacteria overgrow in the small intestine, they ferment carbohydrates before they can be absorbed, producing hydrogen and/or methane gas that causes bloating, distension, pain, altered bowel habits, and nutrient malabsorption.

SIBO is classified by the predominant gas produced:

• Hydrogen-dominant SIBO — associated with diarrhea-predominant symptoms; caused by hydrogen-producing bacteria (Escherichia, Klebsiella, Enterobacter)
• Methane-dominant SIBO (IMO — Intestinal Methanogen Overgrowth) — associated with constipation; caused by methane-producing archaea (Methanobrevibacter smithii); methane slows intestinal motility
• Hydrogen sulfide SIBO — associated with diarrhea, flatulence with sulfurous odor, and systemic toxicity from hydrogen sulfide absorption

Causes & Risk Factors

SIBO develops when the small intestine's natural defense mechanisms are compromised:

• Impaired migrating motor complex (MMC) — the MMC is the "housekeeping wave" that sweeps bacteria from the small intestine between meals; impaired MMC (from hypothyroidism, diabetes, opioid use, stress) allows bacterial accumulation
• Low stomach acid (hypochlorhydria) — gastric acid is the first line of defense against bacterial overgrowth; PPI use, H. pylori infection, and aging reduce acid production
• Ileocecal valve dysfunction — the ileocecal valve prevents backflow of colonic bacteria into the small intestine; dysfunction allows retrograde colonization
• Prior food poisoning / acute gastroenteritis — Campylobacter and other pathogens produce cytolethal distending toxin (CDT) that triggers autoimmune damage to the MMC (post-infectious IBS/SIBO)
• Structural abnormalities — adhesions, strictures, and diverticula create stagnant pockets allowing bacterial accumulation
• Immune deficiency — reduced secretory IgA and mucosal immunity allow bacterial overgrowth

SIBO & Systemic Disease

SIBO is not merely a digestive condition. Bacterial fermentation products — including LPS, D-lactic acid, and hydrogen sulfide — are absorbed into the portal circulation, driving hepatic inflammation (relevant in NAFLD), systemic immune activation, and neuroinflammation via the gut-brain axis. SIBO is associated with rosacea, restless leg syndrome, fibromyalgia, ME-CFS, and multiple autoimmune conditions.

Diagnosing SIBO

SIBO is diagnosed via lactulose or glucose breath testing, measuring exhaled hydrogen and methane after ingestion of a fermentable substrate. Comprehensive stool analysis and organic acids testing provide complementary information about microbial composition and metabolic activity.

Treating SIBO

SIBO treatment requires a multi-phase approach:

• Phase 1: Eradication — rifaximin (antibiotic, non-absorbable) is the gold standard for hydrogen SIBO; rifaximin + neomycin or metronidazole for methane IMO. Herbal antimicrobials (berberine, oregano oil, allicin, neem) demonstrate comparable efficacy to rifaximin in clinical trials and are preferred by many functional medicine practitioners for their broader antimicrobial spectrum and lower resistance risk.
• Phase 2: Motility restoration — prokinetics (low-dose erythromycin, prucalopride, ginger, 5-HTP) restore MMC function to prevent recurrence
• Phase 3: Gut restoration — rebuilding the gut microbiome and epithelial barrier after eradication
• Phase 4: Root cause correction — addressing underlying drivers (hypothyroidism, hypochlorhydria, structural issues) to prevent relapse

Part II: Leaky Gut (Intestinal Hyperpermeability)

What Is Leaky Gut?

The intestinal epithelium — a single cell layer lining the gut — is held together by tight junction proteins (claudins, occludins, zonulin) that regulate what passes from the gut lumen into the bloodstream. When these tight junctions are disrupted — by dysbiosis, inflammatory cytokines, gluten (via zonulin release), alcohol, NSAIDs, stress, or pathogenic bacteria — the gut becomes "leaky," allowing bacterial products (LPS, peptidoglycans, flagellin), undigested food antigens, and toxins to translocate into the bloodstream.

This translocation triggers systemic immune activation — the immune system mounts responses against these foreign molecules, producing chronic low-grade inflammation that drives autoimmune disease, metabolic syndrome, neuroinflammation, and hormonal dysregulation.

Causes of Leaky Gut

• Dysbiosis — loss of SCFA-producing bacteria reduces butyrate availability for colonocyte fuel and tight junction maintenance
• Gluten — gliadin peptides trigger zonulin release, opening tight junctions; relevant in celiac disease and non-celiac gluten sensitivity
• Chronic stress — CRH and mast cell activation increase intestinal permeability via neurogenic inflammation
• NSAIDs — inhibit prostaglandin synthesis essential for gut mucosal protection
• Alcohol — directly damages tight junction proteins and promotes dysbiosis
• Processed food emulsifiers — carboxymethylcellulose and polysorbate-80 disrupt the mucus layer and tight junctions
• Infections — pathogenic bacteria (H. pylori, Salmonella, C. difficile) directly damage the epithelial barrier
• Inflammatory cytokines — TNF-α and IFN-γ directly disrupt tight junction protein expression

Testing for Leaky Gut

• Serum zonulin — elevated zonulin indicates tight junction disruption
• LPS antibodies (IgG/IgA/IgM) — indicate bacterial translocation and systemic endotoxemia
• Lactulose:mannitol ratio — urine test measuring differential absorption of two sugars; elevated ratio indicates increased paracellular permeability
• Comprehensive stool analysis — identifies dysbiosis, inflammation (calprotectin, lactoferrin), and secretory IgA levels

Part III: Irritable Bowel Syndrome (IBS)

What Is IBS?

IBS is a functional gastrointestinal disorder characterized by recurrent abdominal pain associated with altered bowel habits (diarrhea, constipation, or mixed) in the absence of structural pathology. It affects 10–15% of the global population and is the most common reason for gastroenterology referral. Despite its "functional" label, IBS has identifiable biological drivers:

• SIBO — present in up to 80% of IBS patients; bacterial fermentation drives gas, bloating, and altered motility
• Visceral hypersensitivity — a form of central sensitization applied to gut sensation; the gut-brain axis amplifies normal gut signals into pain
• Gut dysbiosis — altered microbiome composition drives mucosal inflammation and motility changes
• Mast cell activation — mucosal mast cells release histamine and tryptase that sensitize enteric nerves and increase gut permeability
• Post-infectious IBS — following acute gastroenteritis, autoimmune damage to the MMC (via CDT-B antibodies) produces SIBO and IBS
• Gut-brain axis dysregulation — bidirectional dysfunction between the gut and CNS amplifies pain perception and alters motility

IBS Subtypes

• IBS-D (diarrhea-predominant) — often driven by hydrogen SIBO, bile acid malabsorption, or mast cell activation
• IBS-C (constipation-predominant) — often driven by methane IMO, slow transit, or hypothyroidism
• IBS-M (mixed) — alternating diarrhea and constipation; often driven by dysbiosis and visceral hypersensitivity

Part IV: Inflammatory Bowel Disease (IBD)

Crohn's Disease

Crohn's disease is a chronic, transmural inflammatory condition that can affect any segment of the GI tract from mouth to anus, most commonly the terminal ileum and colon. It is characterized by skip lesions, granuloma formation, and a relapsing-remitting course. Pathophysiology involves dysregulated mucosal immunity — particularly Th1 and Th17 cell overactivation — against commensal gut bacteria in genetically susceptible individuals. Key drivers include NOD2 gene mutations impairing bacterial recognition, gut dysbiosis (reduced Faecalibacterium prausnitzii, increased Escherichia coli), and gut barrier dysfunction. Extraintestinal manifestations include arthritis, uveitis, primary sclerosing cholangitis, and skin conditions.

Ulcerative Colitis (UC)

UC is a chronic inflammatory condition confined to the colonic mucosa, producing continuous inflammation from the rectum proximally. It is characterized by mucosal ulceration, bloody diarrhea, urgency, and cramping. Pathophysiology involves Th2 and Th17 overactivation, impaired mucosal barrier function, and dysbiosis with reduced microbial diversity. UC carries a significantly increased risk of colorectal cancer with long disease duration.

IBD Pathophysiology

Both Crohn's and UC share core pathological features:

• Dysregulated mucosal immunity with NF-κB hyperactivation driving TNF-α, IL-6, IL-12, and IL-23 production
• Gut dysbiosis — reduced microbial diversity, loss of SCFA-producing species, increased pathobionts
• Gut barrier dysfunction — impaired tight junctions and mucus layer
• Gut-brain axis dysregulation — visceral hypersensitivity and psychological comorbidity (anxiety, depression affect 30–40% of IBD patients)
• Mitochondrial dysfunction in colonocytes impairing mucosal energy metabolism and repair (Seyfried et al.)

Andries et al. have highlighted the gut-immune axis as central to IBD pathogenesis, noting that restoration of microbial diversity and gut barrier integrity is foundational to disease remission and prevention of relapse.

Part V: The Gut-Brain Axis

Bidirectional Communication

The gut-brain axis is the bidirectional communication network connecting the enteric nervous system (ENS — the "second brain" containing 500 million neurons) with the central nervous system via:

• The vagus nerve — the primary neural highway of the gut-brain axis; 80–90% of vagal fibers are afferent (gut-to-brain), transmitting microbial signals, inflammatory status, and nutrient information to the brain
• The HPA axis — stress activates the HPA axis, releasing cortisol that alters gut motility, permeability, and microbial composition
• Immune signaling — gut-derived cytokines and LPS reach the brain via the bloodstream, activating microglia and driving neuroinflammation
• Neurotransmitter production — gut bacteria produce serotonin (90–95% of body's total), GABA, dopamine precursors, and short-chain fatty acids that directly influence brain function
• Tryptophan metabolism — gut bacteria regulate tryptophan availability for serotonin vs. kynurenine pathway metabolism; dysbiosis shifts toward kynurenine, producing neuroactive metabolites associated with depression and neuroinflammation

Gut-Brain Axis in Disease

Gut-brain axis dysregulation is implicated across the full spectrum of conditions covered in our education hub:

• Depression, anxiety, ADHD, and Alzheimer's — gut dysbiosis drives neuroinflammation and neurotransmitter dysregulation
• Fibromyalgia and chronic pain — gut-derived inflammatory signals amplify central sensitization
• Autoimmune disease — gut dysbiosis drives systemic immune dysregulation and molecular mimicry
• Metabolic syndrome and T2DM — gut-liver axis dysregulation drives insulin resistance and NAFLD
• Hormonal disorders — estrobolome dysregulation drives estrogen dominance; gut-thyroid axis impairs T4-to-T3 conversion

Vagal Tone & Gut-Brain Health

Vagal tone — the activity level of the vagus nerve — is a critical determinant of gut-brain axis health. High vagal tone is associated with reduced inflammation, improved gut motility, better stress resilience, and superior mental health outcomes. Vagal tone can be improved through diaphragmatic breathing, cold water exposure, humming and singing, meditation, exercise, and omega-3 supplementation.

Part VI: Integrative Approaches

Low Dose Naltrexone (LDN)

LDN has demonstrated remarkable efficacy in IBD, with clinical trials showing significant improvements in Crohn's disease activity scores and mucosal healing. Its mechanisms are directly relevant: TLR4 antagonism reduces mucosal macrophage activation; endorphin upregulation supports mucosal immune regulation; and TNF-α and IL-6 reduction addresses the core inflammatory drivers of IBD. Cairns et al. have documented LDN's efficacy in Crohn's disease, with pediatric and adult trials demonstrating remission induction and maintenance. In IBS, LDN's visceral analgesic effects via opioid receptor modulation reduce pain and improve quality of life. Andries et al. have highlighted LDN's gut-immune axis modulation as foundational to its efficacy in gut inflammatory conditions.

CBD & THC

The endocannabinoid system is densely expressed throughout the gut — CB1 receptors regulate gut motility, secretion, and visceral sensation; CB2 receptors on mucosal immune cells regulate inflammation. CBD's gut-specific mechanisms include CB2-mediated mucosal immune modulation reducing IBD inflammation; gut microbiome modulation increasing Akkermansia muciniphila; intestinal permeability reduction; mast cell stabilization relevant in IBS-D and MCAS-associated gut symptoms; and visceral analgesic effects via TRPV1 and 5-HT1A. THC reduces gut motility (relevant in IBS-D and Crohn's diarrhea), reduces visceral pain via CB1, and stimulates appetite in IBD-related anorexia. See our Buyer's Guide to CBD & THC Oils for dosing guidance.

Herbal Antimicrobials for SIBO

• Berberine (500mg 3x/day) — broad-spectrum antimicrobial against SIBO organisms; comparable to rifaximin in clinical trials; simultaneously restores gut microbiome diversity and reduces intestinal inflammation
• Oregano oil (200mg 2–3x/day) — potent antimicrobial via carvacrol and thymol; effective against hydrogen and methane SIBO
• Allicin (garlic extract, 450mg 3x/day) — particularly effective against methane IMO; comparable to rifaximin + neomycin in clinical trials
• Neem (300mg 2x/day) — broad-spectrum antimicrobial and anti-biofilm agent
• Partially hydrolyzed guar gum (PHGG, 5g/day) — prebiotic fiber that selectively feeds beneficial bacteria while supporting MMC function

Gut Barrier Repair

• L-Glutamine (5–10g/day) — primary fuel for intestinal epithelial cells; essential for tight junction repair in leaky gut
• Zinc carnosine (75mg/day) — clinically proven to repair tight junctions and reduce gut permeability
• Colostrum (2–4g/day) — rich in immunoglobulins, lactoferrin, and growth factors supporting epithelial repair
• Deglycyrrhizinated licorice (DGL) — supports mucus layer production and gut mucosal healing
• Slippery elm and marshmallow root — demulcent herbs coating and soothing the intestinal mucosa
• Bone broth — provides glycine, proline, and collagen precursors for gut epithelial repair

Probiotics for Gut Conditions

• Lactobacillus rhamnosus GG — most studied probiotic; reduces gut permeability, supports barrier integrity
• Saccharomyces boulardii — reduces C. difficile, antibiotic-associated diarrhea, and IBD inflammation; inhibits pathogen adhesion
• VSL#3 / multi-strain high-dose probiotics — clinical evidence in UC remission maintenance
• Lactobacillus plantarum — reduces IBS symptoms, improves gut barrier function
• Bifidobacterium infantis — reduces IBS pain and bloating; supports Treg induction
• Note on SIBO: Probiotics should be used cautiously during active SIBO treatment; Lactobacillus-containing probiotics may worsen hydrogen SIBO in some patients. Saccharomyces boulardii and soil-based organisms (Bacillus species) are generally better tolerated during SIBO treatment.

Dietary Approaches

• Low-FODMAP diet — reduces fermentable substrates feeding SIBO and IBS symptoms; effective short-term but not intended as a long-term diet
• Specific Carbohydrate Diet (SCD) — eliminates complex carbohydrates feeding pathogenic bacteria; clinical evidence in Crohn's and UC
• Anti-inflammatory diet — Mediterranean-style, high fiber, polyphenol-rich; supports microbial diversity and mucosal healing
• Elemental diet — pre-digested amino acid-based formula; highly effective for SIBO eradication (80–85% success rate) by starving bacteria of fermentable substrates
• Gluten elimination — reduces zonulin-mediated gut permeability; essential in celiac disease and beneficial in non-celiac gluten sensitivity

Motility Support

• Ginger (500–1000mg/day) — prokinetic; stimulates MMC activity and gastric emptying; reduces SIBO recurrence
• 5-HTP (50–100mg between meals) — serotonin precursor supporting MMC function; take between meals to avoid interference with food-stimulated gut activity
• Iberogast — herbal prokinetic combination with clinical evidence in functional dyspepsia and IBS
• Magnesium citrate/oxide — osmotic laxative supporting motility in IBS-C and methane IMO

Integrative Gut Health Protocol

SIBO:

• Herbal antimicrobials (berberine + oregano oil + allicin) for 4–6 weeks
• Prokinetics (ginger + 5-HTP) between meals
• Low-FODMAP or elemental diet during treatment
• Saccharomyces boulardii during treatment; full probiotic restoration after

Leaky Gut:

• L-Glutamine (5–10g/day) + Zinc carnosine (75mg/day) + Colostrum
• Dysbiosis correction (probiotics, prebiotics, dietary fiber)
• Remove triggers (gluten, NSAIDs, alcohol, emulsifiers)
• Stress management — vagal tone support

IBS:

• SIBO testing and treatment if positive
• LDN (1.5–4.5mg/day) — visceral analgesia, mucosal immune modulation
• CBD (25–75mg/day) — mast cell stabilization, visceral pain, gut motility
• Peppermint oil (enteric-coated, 180mg 3x/day) — antispasmodic; clinical evidence in IBS
• Gut-directed hypnotherapy or MBSR — gut-brain axis modulation

IBD (Crohn's & UC):

• LDN (1.5–4.5mg/day) — mucosal healing, TNF-α suppression
• CBD + THC — mucosal immune modulation, pain, appetite
• Curcumin (1000–2000mg/day enhanced) — NF-κB suppression, mucosal healing; clinical evidence in UC maintenance
• Omega-3 (3–4g/day) — anti-inflammatory eicosanoids, mucosal protection
• VSL#3 or high-dose multi-strain probiotics — UC remission maintenance
• Exclusive enteral nutrition (EEN) — for Crohn's remission induction
• Vitamin D3 (target 60–80 ng/mL) — mucosal immune regulation

This article is for educational purposes only and does not constitute medical advice. Gut conditions require individualized assessment and management by qualified healthcare providers.

Key References

• Cairns, D.M. et al. — LDN in IBD: mucosal healing and immune modulation in Crohn's disease and ulcerative colitis.
• Andries, K. et al. — Gut-immune axis, gut-brain axis, and systemic disease: the central role of the microbiome.
• Noori, S. et al. — Natural anti-inflammatory and antimicrobial compounds in gut health restoration.
• Seyyedabadi, B. et al. — Mucosal immune dysregulation and mitochondrial dysfunction in IBD.
• Seyfried, T.N. et al. — Mitochondrial dysfunction in colonocyte energy metabolism and IBD pathogenesis.